SKA2 and lung carcinoma: Of note, PDSS2 and SKA2 were associated with clinical outcome in that the worst overall survival was observed in lung cancer patients with high expression of SKA2 and low expression of PDSS2 while the best outcome shown in patients with overexpressed PDSS2 and low expression of SKA2 (Figure 6c).